OncoAlert
@OncoAlert

🌐 Worldwide oncology professionals network | Run by oncologists, for colleagues | All tumor types | Non-profit 🚨 We are #OncoAlert | Oncology360°

 Worldwide
OncoAlert360.com
Joined March 2019
5,874 Photos and videos
Pinned Tweet
OncoAlert
@OncoAlert
Sep 25
🚨 FDA Priority Review granted for durvalumab plus neoadjuvant enfortumab vedotin in muscle-invasive #BladderCancer : VOLGA Update Source: AstraZeneca The submission is supported by Phase III VOLGA results showing statistically significant and clinically meaningful improvements in event-free survival and overall survival. @DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @AlbigesL, @cdanicas, @amerseburger, @sonpavde, @DrDanielHeng, @declangmurphy, @seanmmcbride, @HHammersMD, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @scocmem, @ravikanesvaran, @AmandaNizamMD, @drenriquegrande, @BraunMDPhD, @EfstathiouEleni, @nataliagandur, @crisbergerot, @realbowtiedoc, @FernandoOnco, @ElisaAgostinett, @to_be_elizabeth, @MarioBalsaMD, @BRicciutiMD, @HHorinouchi, @UOzkerim, @p_ciracimd, @DrMirallas
12
21
6,086
OncoAlert retweeted
Dr. Nina Niu Sanford
@NiuSanford
13h
It’s easy to criticize RT trials for aspirational effect sizes (I’ve done it myself). But these studies v difficult to accrue ($, tech avail off trial). A smaller effect size can make N infeasible. Alternative endpoints/stats = potential solutions, but this is current reality.
2
7
19
1,302
OncoAlert retweeted
PDBrown
@PDBrownOnc
Sep 25
🚨🚨 Randomized Trial #ASTRO26 Resected Brain Met fractionated SRS vs single fraction SRS post-op cavity 🚨 • fSRS superior surgical bed control • No diff AEs • fSRS standard of care for resected larger brain met
8
52
134
8,559
RT @niklas_kluemper: More evidence that NECTIN4 matters as a biomarker for EV+pembrolizumab! 🎯 Important independent validation from @Matt…
15
128
OncoAlert retweeted
ASTRO
@ASTRO_org
13h
#ASTRO26: Join us on Saturday, Sept. 26 for an Industry Satellite Symposium on "Tumor Board: Integrating Immunotherapy With Definitive and Perioperative Radiation Strategies in Stage I-III NSCLC" Commonwealth A-B, Westin Boston Seaport District Hotel 6:30 p.m. - 8:00 p.m. ET: Dinner & Hybrid Symposium With speakers Joe Chang, MD, PhD, MS, FASTRO, Nitin Ohri, MD, MS, & Hossein Borghaei, DO, MS. Learn more: bit.ly/4yJBbfk @AstraZeneca @JoeChangMD @HosseinBorghaei
2
8
676
#NSCLC 🫁 oligoprogressive #SBRT 🎯 #ASTRO26 @ASTRO_org @BenLok 🚦
6
7
752
#NSCLC 🫁☢️ @ASTRO_org #ASTRO26 @PranshuMohindra
Made with AI
1
3
11
588
OncoAlert retweeted
IJGC
@IJGConline
10h
This #GynecologicCancerAwarenessMonth, let's stand with every woman affected by #GynecologicCancer 💜 Support starts with: 👂 Listening 🫶 Presence 📄 Accurate information 🏥 Access to timely, high-quality care By speaking openly, we can challenge misconceptions, reduce stigma, and ensure that no one faces a gynecologic cancer diagnosis alone. Together, we can support patients and eliminate the stigma surrounding gynaecologic cancers. @pedroramirezMD @RParejaGineOnco @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @Suvidyasingh20 @ohadfeld @WorldGOday
1
2
6
451
OncoAlert retweeted
Hidehito HORINOUCHI
@HHorinouchi
16h
🆙 #ESMO26 Rapid Oral: #LCSM Non-Mets, others 🔥MDT-BRIDGE: ctDNA Clearance (CL) During Neoadjuvant Treatment and Its Association With Outcomes in Patients With Resectable/Borderline Resectable Stage IIB–IIIB NSCLC 🎙️ @DoctorJSpicer 🔢LBA62 ☑️NCT05925530 🔗 cslide.ctimeetingtech.com/es… @OncoAlert @Larvol @myESMO @IASLC
Hidehito HORINOUCHI
@HHorinouchi
Sep 13
🆙#WCLC26 #LCSM Oral Session 🔥MDT-BRIDGE: Neoadjuvant Durvalumab + Chemotherapy for Resectable/Borderline Resectable Stage IIB-IIIB NSCLC 🎙️ @MartinReck2 🔢OA04.02 🎯Resection Rate 74.6%; pCR 27.3% and 12-Mo EFS 90.1% in Resectable Cohort ☑️NCT05925530 🔗 cattendee.abstractsonline.co… @OncoAlert @Larvol @IASLC
7
8
1,689
Less is more — demonstrated once again — neuropathy once established is a lifelong toxicity for patients to carry and this study demonstrates that we can give our patients back their lives without significant compromise -this study is very consequential as we have moved to the molecularly targeted era in advanced stages - limited induction chemo then let biology dominate the rest of the course @OncBrothers @OncoAlert @MayoCancerCare
Bassam Sonbol
@sonbol_bassam
Sep 26
This is one of my favorite papers we’ve published , led by our great Mayo resident @WallaceKleinS “Reduced oxaliplatin exposure in gastrointestinal cancers: A systematic review and meta-analysis” We already know from maintenance trials in mCRC that stopping oxaliplatin after 3–4 months is not detrimental for PFS/OS and is associated with less neuropathy. The question in 2026: what is the evidence in mCRC, the adjuvant setting, and other GI cancers? Is there a situation where oxaliplatin is still needed beyond 3–4 months of induction? In other words — is reduced oxaliplatin exposure associated with worse DFS or PFS across GI cancers? We did a meta-analysis across GI cancers and settings: • No statistically significant survival difference overall • Lower neuropathy and grade ≥3 adverse events Take-home: don’t keep oxaliplatin going beyond 3–4 months. These findings support limiting exposure to improve the therapeutic index of oxaliplatin-based chemo across GI settings. sciencedirect.com/science/ar… @OncoAlert @MayoCancerCare #GIonc @GIcancerDoc @WallaceKleinS
1
9
24
3,663
IMpassion050 final results: Adding atezolizumab to HER2-directed therapy didn't significantly improve EFS or DFS in high-risk HER2-positive early #BreastCancer 3 yrs EFS: 91.4% vs 89.0% HR 0.90 (95% CI 0.50-1.59) esmoopen.com/article/S2059-7… @OncoAlert #bcsm @myESMO
2
8
20
629
ZEAL-1L: adding niraparib to pembrolizumab maintenance did not improve PFS in unselected advanced NSCLC. 🫁 5.55 vs 5.55 months; HR 1.00. The biological rationale was compelling, but the clinical benefit was absent. jto.org/article/S1556-0864%2… @OncoAlert #lcsm #LungCancer
2
7
17
1,035
Happy to share two additional 🧩 of the neoadjuvant/perioperative puzzle of MIBC slated to be disclosed #ESMO26 - Friday 23 Oct: CA078 trial (#ENERGIZE) Randomized phase III periop Nivo-GC vs GC - Sat 24 Oct: Long term results of #GDFATHERNeo Phase II neoadj Nivo + Visugromab vs placebo #GFD15 @myESMO @OncoAlert @sonpavde @shilpaonc @SanRaffaeleMI @MyUniSR @urotoday
2
15
28
1,164
OncoAlert retweeted
OncoAlert
@OncoAlert
Sep 21
Dear Colleagues, Join @OncoAlert 🚨 LIVE in FLORENCE Italy Oct 9–10, for the 2nd International Multidisciplinary Consensus on Integrating Radiation Therapy with New Systemic Treatments (endorsed by ESTRO) THERE ARE ONLY 1️⃣ 5️⃣ SPOTS LEFTfor FREE Registration (First Come First Serve) REGISTER HERE 👉 buff.ly/I8wKRpo JOIN US and Top experts building evidence-based recommendations across breast, head & neck, and genitourinary cancers!
7
11
1,660
OncoAlert retweeted
Stephen V Liu, MD
@StephenVLiu
Sep 26
Early insights into resistance to HER2 TKIs in NSCLC emerged at #WCLC26. Zongertinib & sevabertinib now both approved as 1L+ treatment for advanced NSCLC with a HER2 TKD mt. While efficacy similar, these are distinct agents and we need to learn how to leverage those differences.
2
16
56
4,507
First selfie of #ASTRO26 with @AgustinGilardi3 🇦🇷 doing a fellow in 🇨🇦 @ASTRO_org @Solar_Latam #SATRO @centrodeanfunes
1
15
1,215
OncoAlert retweeted
Hidehito HORINOUCHI
@HHorinouchi
17h
🆙 #ESMO26 Rapid Oral 2: #LCSM Mets 🔥ROSETTA Lung-107: A Global Phase 2, Open-Label Trial of Pumitamig (PD-L1 × VEGF-A bsAb) + Docetaxel Post-Chemoimmunotherapy in mNSCLC 🎙️ @cbcbc1971 🔢LBA76 🔗 cslide.ctimeetingtech.com/es… @OncoAlert @Larvol @myESMO @IASLC
Hidehito HORINOUCHI
@HHorinouchi
May 31
🔁REVIEW #ASCO26 #LCSM Rapid Oral 🔥ROSETTA Lung-02: Pumitamig (PD-L1×VEGF-A bsAb) + Chemo in 1L NSCLC ✅ORR 70.0% ✅NSQ ORR 66.7%, SQ ORR 73.7% ✅Active across all PD-L1 levels 🎙️ @peters_solange 🔢8513 ☑️NCT06712316 🔗 asco.org/abstracts-presentat… @OncoAlert @Larvol @IASLC @ASCO
3
4
1,253
OncoAlert retweeted
Hidehito HORINOUCHI
@HHorinouchi
18h
🆙 #ESMO26 Rapid Oral 1: #LCSM Mets 🔥COCOON: Improving Prevention of Moderate to Severe Dermatologic Adverse Events in EGFR-Mutant Advanced NSCLC Treated With First-Line Subcutaneous Amivantamab + Lazertinib: First Results From a New Cohort 🎙️ @cbcbc1971 🔢2700RO ☑️NCT06120140 🔗 cslide.ctimeetingtech.com/es… @OncoAlert @Larvol @myESMO @IASLC @EGFRResisters
Hidehito HORINOUCHI
@HHorinouchi
27 Mar 2025
⏰NOW OUT‼️#ELCC25 🔥COCOON🦋: Preventing Moderate to Severe Dermatologic Adverse Events in First-line EGFR-mutant Advanced NSCLC Treated with Amivantamab Plus Lazertinib 🎙️ @nicogirardcurie 🎯AEs ≥G2: OR 0.19 (95% CI, 0.09–0.40) ✅NCT06120140 #LCSM @OncoAlert @myESMO @IASLC
4
11
1,911
OncoAlert retweeted
Hidehito HORINOUCHI
@HHorinouchi
18h
🆙 #ESMO26 Rapid Oral 1: #LCSM Mets 🔥DESTINY-Lung04: First-Line Trastuzumab Deruxtecan (T-DXd) in Patients With HER2-Mutant (HER2m) NSCLC: Patient-Reported Outcomes 🎙️Dr. Silvia Novello 🔢LBA74 ☑️NCT05048797 🔗 cslide.ctimeetingtech.com/es… @OncoAlert @Larvol @IASLC @myESMO
Hidehito HORINOUCHI
@HHorinouchi
Sep 14
🆙#WCLC26 #LCSM Plenary Session 🔥DESTINY-Lung04: First-Line Trastuzumab Deruxtecan (T-DXd) in Patients With Metastatic HER2-Mutant NSCLC: Primary Results 🎙️ @JuliaRotow 🎯PFS HR 0.63 (95%CI 0.50-0.79) 🎯OS HR 1.15 (95%CI 0.88-0.92) 🔢PL03.08 ☑️NCT05048797 🔗 cattendee.abstractsonline.co… @OncoAlert @Larvol @IASLC
3
11
1,939
OncoAlert retweeted
PDBrown
@PDBrownOnc
20h
🚨🚨Randomized Trial #ASTRO26 Small Cell Lung Cancer Brain Met fractionated SRS vs HA-WBRT 🚨 • No diff time to cognitive failure, neurologic death • SRS ↑↑ OS • ↑↑ AEs HA-WBRT • SRS standard of care SCLC brain met
4
64
141
9,228
OncoAlert retweeted
Jeff White@PRJeffWhite
19h
Happy #ASTRO26 Saturday. Yes it’s gonna be wet, but we are doing it! See you soon! @ASTRO_org
3
29
2,284
Load more